2021
DOI: 10.3390/cells10010057
|View full text |Cite
|
Sign up to set email alerts
|

Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification

Abstract: Calcific aortic valve disease (CAVD) accompanies inflammatory cell infiltration, fibrosis, and ultimately calcification of the valve leaflets. We previously demonstrated that dipeptidyl peptidase-4 (DPP-4) is responsible for the progression of aortic valvular calcification in CAVD animal models. As evogliptin, one of the DPP-4 inhibitors displays high specific accumulation in cardiac tissue, we here evaluated its therapeutic potency for attenuating valvular calcification in CAVD animal models. Evogliptin admin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
19
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 27 publications
(19 citation statements)
references
References 53 publications
0
19
0
Order By: Relevance
“…Refametinib and doxycycline were shown to reduce macrophage infiltration in mouse models with latent aortic valve disease, slowing its progression [ 146 ]. Evogliptin, an inhibitor of the enzyme dipeptidyl peptidase-4, was shown to attenuate aortic valve calcification through a reduction in pro-inflammatory cytokines (Il-6, IL-1, TNF-alpha) and the inhibition of macrophage infiltration in a rabbit model [ 149 ]. Evogliptin has also been shown to be useful as an anti-atherosclerosis therapy via its ability to inhibit vascular inflammation [ 150 ].…”
Section: Targeting Macrophages In the Treatment Of Cvdmentioning
confidence: 99%
“…Refametinib and doxycycline were shown to reduce macrophage infiltration in mouse models with latent aortic valve disease, slowing its progression [ 146 ]. Evogliptin, an inhibitor of the enzyme dipeptidyl peptidase-4, was shown to attenuate aortic valve calcification through a reduction in pro-inflammatory cytokines (Il-6, IL-1, TNF-alpha) and the inhibition of macrophage infiltration in a rabbit model [ 149 ]. Evogliptin has also been shown to be useful as an anti-atherosclerosis therapy via its ability to inhibit vascular inflammation [ 150 ].…”
Section: Targeting Macrophages In the Treatment Of Cvdmentioning
confidence: 99%
“…107 In a study of calcific aortic valve disease (CAVD) animal model, evogliptin attenuated valvular calcification and CAVD progression via inhibiting inflammatory cytokine expression, fibrosis, and calcification. 108 Taken together, the findings thus far indicate that DPP-4 inhibitors can be used novel therapeutic target or treatment strategies for stressrelated vascular disorders, although further studies are needed for clinical application.…”
Section: Protective Effects Of Dpp-4 Inhibitors Against Vascular Disease In Siasmentioning
confidence: 94%
“…Thus, antidiabetic drugs that suppress inflammation also suppress calcification in animal models. For example, evogliptin, a dipeptidyl peptidase-4 inhibitor used in type 2 diabetes mellitus, was shown to suppress inflammatory cytokine gene expression and calcific lesions in mice and to reduce matrix calcification in human valve interstitial cell cultures, suggesting a potential therapeutic agent for calcific aortic valve disease [145]. Newer drugs, such as sodium glucose co-transporter-2 inhibitors, also provide beneficial cardiovascular effects [146], at least in part, through reducing circulating levels of inflammatory cytokines [6].…”
Section: Inflammatory Cytokinesmentioning
confidence: 99%